Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04248920
Other study ID # 9045
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 12, 2022
Est. completion date December 11, 2023

Study information

Verified date January 2024
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Analysis of emergency department (ED) visits with a billing code for 'epilepsy' or 'seizure' found up to 37% are eligible for deferral. This study is a randomized controlled trial (RCT) of the Clinic To Community© program (C2C) as an intervention for adults with epilepsy visiting emergency departments at a mid size hospital in Ontario, Canada. Participants in the intervention arm receive patient education to improve knowledge of epilepsy and access to community-based services. Participants in the control group are wait-listed and receive patient education 12 months later. The study objective is to successfully implement, recruit and retain participants for this intervention and evaluate whether C2C will reduce the frequency of ED visits, reduce felt stigma and improve quality of life, epilepsy knowledge, and self-management skills.


Description:

Emergency care for epilepsy can be appropriate and even life-saving, but up to 37% of emergency department (ED) visits by persons with epilepsy (PWE) are potentially deferrable, resulting from persons with known epilepsy and uncomplicated seizures. Past studies have shown that low self-management confidence among PWE leads to frequent emergency visits to the hospital. Other factors associated with increased use of EDs are increased seizure frequency, reduced medication, sub-optimal self-management, increased anxiety, increased depression, increased felt-stigma, and lower social and medical epilepsy knowledge. In one catchment area in Ontario, Canada, the Southwest Local Health Integration Network (LHIN), there are an estimated 7508 prevalent cases of epilepsy associated with the use of approximately $55 million/year of provincial healthcare services. In addition, there are an estimated 433 incident cases costing an additional $4.6 million/year. Hospital care (including ED visits) accounts for 35.5% of the total cost equating to $21 million/year. Eliminating the 37% of deferrable ED visits equates to saving almost $8 million/year. The Clinic to Community© (C2C) epilepsy education program has been developed using best practices for patient education. The content has been divided into an introductory 60 minute face-to-face session supported by strategy sheets that can be accessed online at www.clinictocommunity.ca The Clinic To Community© program recognizes that epilepsy is unique among chronic conditions in that PWE lose their ability to make choices during a seizure and depend on the decisions of others including family, friends and colleagues to keep them safe. Many patients seek care in the ED to reduce their anxiety and for reassurance and that upon discharge from the ED, the inability to receive a prompt specialist appointment leads to the continued use of ED for these same patients. This is a parallel, pilot randomized controlled trial (RCT) comparing the Clinic To Community© program plus treatment-as-usual (TAU) with TAU only (i.e. wait-list control). This study will not interfere with patients' clinical care. Eligible patients visiting a participating ED will be given information about the study and if they agree, will be referred. The C2C program will be delivered in-person, one-on-one for 60 minutes by appointment on a rolling basis to minimize wait-times and allow timely access to the intervention. All participants will complete questionnaires before randomization and 12 months after randomization.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date December 11, 2023
Est. primary completion date December 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults (aged =18 years) visiting a participating ED for a seizure or an epilepsy-related concern. 2. Adults on anti-seizure medication prior to coming to the ED or prescribed anti-seizure medication at the ED. 3. Providing informed consent and having sufficient English language skills to complete questionnaires and participate in the intervention. Exclusion Criteria: 1. Previous participation in the C2C program. 2. Known diagnosis of psychogenic non-epileptic seizures (PNES).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Clinic to Community Education Program
The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).

Locations

Country Name City State
Canada London Health Sciences Centre London Ontario

Sponsors (2)

Lead Sponsor Collaborator
Lawson Health Research Institute Ontario Brain Institute

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Bautista RE, Glen ET, Wludyka PS, Shetty NK. Factors associated with utilization of healthcare resources among epilepsy patients. Epilepsy Res. 2008 May;79(2-3):120-9. doi: 10.1016/j.eplepsyres.2008.01.003. Epub 2008 Mar 12. — View Citation

Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R. Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery. Ont Health Technol Assess Ser. 2012;12(18):1-41. Epub 2012 Jul 1. — View Citation

Couldridge L, Kendall S, March A. A systematic overview--a decade of research'. The information and counselling needs of people with epilepsy. Seizure. 2001 Dec;10(8):605-14. doi: 10.1053/seiz.2001.0652. — View Citation

Kapoor, Deepa, Joubert, Gary, Thind, Amardeep, Secco, Mary, Speechley, Kathy Nixon. Number of Potentially Deferrable Patients Presenting to Emergency Departments in London with Seizures. Epilepsia 2007; Vol 48, Supplement 6

Noble AJ, Mathieson A, Ridsdale L, Holmes EA, Morgan M, McKinlay A, Dickson JM, Jackson M, Hughes DA, Goodacre S, Marson AG. Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational 'Collaborate' project. BMJ Open. 2019 Nov 2;9(11):e031696. doi: 10.1136/bmjopen-2019-031696. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Effect on quality of life using World Health Organization Quality of Life (WHOQOL) Change from baseline measured by World Health Organization Quality of Life (WHOQOL) - Abbreviated (BREF), 30-item measure of quality of life, generic-HRQOL instrument. Baseline (0) and 12 months
Other Effect on activities of daily living using Sheehan Disability Scale Change from baseline measured by the Sheehan Disability Scale is 5-items for patient-rated measure of disability and impairment. Baseline (0) and 12 months
Other Effect on anxiety using Generalized Anxiety Disorder 7-item (GAD-7) scale Change from baseline using the Generalized Anxiety Disorder 7-item (GAD-7) scale, 7-item scale evaluating generalized anxiety. Generates an overall anxiety score, with scores above 10 indicative of moderate-severe anxiety. Baseline (0) and 12 months
Other Effect on depressive symptoms based on Quick Inventory of Depressive Symptomatology Change from baseline using the Quick Inventory of Depressive Symptomatology, 14-item scale evaluating depressive symptoms. Baseline (0) and 12 months
Other Effect on sleep quality using Pittsburgh Sleep Quality Index (25-items) Change from baseline measured by the Pittsburgh Sleep Quality Index, 25-item scale evaluating sleep quality. Baseline (0) and 12 months
Other Effect on suicide ideation using Columbia-Suicide Severity Rating Scale (C-SSRS) Screener Change from baseline measured by the C-SSRS Screener, a 6-item scale evaluating suicidal ideation. Baseline (0) and 12 months
Other Effect on Psychiatric comorbidities using Brief Symptom Inventory Change from baseline measured by 53-items covering nine symptom dimensions: Somatization, Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation and Psychoticism; and three global indices of distress: Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total. The global indices measure current or past level of symptomatology, intensity of symptoms, and number of reported symptoms, respectively Baseline (0) and 12 months
Primary Rate of engagement with the Clinic To Community© (C2C) program Evaluated by rate of ED referrals, rate of recruitment, rate of retention, and proportion who receive support education. Throughout study completion, approximately 2 years
Secondary Frequency of epilepsy-related emergency department (ED) visits over the next 12 months Change from baseline in frequency of ED visits and health care utilization, adapted from the Canadian Community Health Survey Baseline (0), and 12 months
Secondary Effect of participation in C2C on felt stigma using "Stigma Scale of Epilepsy" Change from baseline in using the Stigma Scale of Epilepsy, 3-item scale asking: "Because of epilepsy, (1) other people are uncomfortable with me; (2) treat me as inferior; (3) prefer to avoid me." Each of those questions is scored on a four-point scale:
0 not at all; 1 yes, maybe; 2 yes, probably; 3 yes, definitely. Total scores range from 0 to 9 and categorized as not stigmatized (score of 0), mild-moderate (1-6) and highly stigmatized (7-9).
Baseline (0) and 12 months
Secondary Effect of participation in C2C on felt stigma using "Epilepsy Stigma Scale" Change from baseline measured by Epilepsy Stigma Scale, a 10-item measure evaluating stigma. Items are measured on a 7-point Likert Scale, from "strongly agree" to "strongly disagree". Baseline (0) and 12 months
Secondary Effect of participation in C2C on self-management skills Change from baseline measured by the Adult Epilepsy Self-Management Measurement Instrument (AESMMI-65) This measure is a 65-item scale assessing the frequency of use of epilepsy self-management practises. Contains seven domains: 1) healthcare communication, 2) treatment management, 3) coping, 4) social support, 5) seizure tracking, 6) wellness, and 7) seizure response. Baseline (0) and 12 months
Secondary Effect of participation in C2C on quality of life Change from baseline measured by Quality of Life in Epilepsy Inventory (QOLIE 10), a 10-item scaled evaluating quality of life in adults with epilepsy. Responses range from "all of the time" to "none of the time" Baseline (0) and 12 months
Secondary Effect of participation in C2C on epilepsy knowledge Change from baseline on the "Thinking About Epilepsy Questionnaire" knowledge subscale. Knowledge is assessed by answering true/false/I don't know Baseline (0) and 12 months
See also
  Status Clinical Trial Phase
Completed NCT00162981 - Clobazam in Subjects With Lennox-Gastaut Syndrome Phase 2
Completed NCT00236886 - Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients Phase 3
Recruiting NCT05477121 - Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
Recruiting NCT04959019 - Exercise for Memory Rehabilitation in Epilepsy N/A
Completed NCT00231556 - A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy Phase 3
Completed NCT04439656 - Detecting Absence Seizures Using Eye Tracking
Completed NCT00319501 - Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures. Phase 3
Completed NCT05241678 - Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome
Completed NCT00266604 - A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Phase 4
Completed NCT00518713 - Clobazam in Patients With Lennox-Gastaut Syndrome Phase 3
Recruiting NCT06399952 - Baker Gordon Syndrome Natural History Study
Completed NCT05297695 - Helicobacter Pylori Eradication Therapy for Epileptic Children Phase 2/Phase 3